After finishing at $70.41 in the prior trading day, Exact Sciences Corp. (NASDAQ: EXAS) closed at $73.74, up 4.73%. In other words, the price has increased by $+3.33 from its previous closing price. On the day, 11350133 shares were traded.
Ratios:
Our goal is to gain a better understanding of EXAS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.21 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 419.23. For the most recent quarter (mrq), Quick Ratio is recorded 2.07 and its Current Ratio is at 2.32. In the meantime, Its Debt-to-Equity ratio is 0.82 whereas as Long-Term Debt/Eq ratio is at 0.79.
On December 14, 2023, Guggenheim started tracking the stock assigning a Buy rating and target price of $90.
On December 13, 2023, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $95.Wolfe Research initiated its Outperform rating on December 13, 2023, with a $95 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 28 ’24 when Condella Sarah sold 2,000 shares for $70.00 per share. The transaction valued at 140,000 led to the insider holds 73,787 shares of the business.
Conroy Kevin T sold 8,271 shares of EXAS for $490,636 on Mar 01 ’24. The President and CEO now owns 1,299,496 shares after completing the transaction at $59.32 per share. On Mar 01 ’24, another insider, LEVANGIE DANIEL J, who serves as the Director of the company, sold 5,000 shares for $57.50 each. As a result, the insider received 287,500 and left with 22,975 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 13.39B and an Enterprise Value of 15.16B. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.35 while its Price-to-Book (P/B) ratio in mrq is 4.25. Its current Enterprise Value per Revenue stands at 6.07 whereas that against EBITDA is 517.81.
Stock Price History:
Over the past 52 weeks, EXAS has reached a high of $100.77, while it has fallen to a 52-week low of $56.05. The 50-Day Moving Average of the stock is 62.11, while the 200-Day Moving Average is calculated to be 71.74.
Shares Statistics:
The stock has traded on average 2.05M shares per day over the past 3-months and 3.68M shares per day over the last 10 days, according to various share statistics. A total of 181.36M shares are outstanding, with a floating share count of 179.64M. Insiders hold about 1.04% of the company’s shares, while institutions hold 90.15% stake in the company. Shares short for EXAS as of Mar 15, 2024 were 6.52M with a Short Ratio of 3.18, compared to 7.27M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.59% and a Short% of Float of 3.62%.
Earnings Estimates
Its stock is currently analyzed by 15 different market analysts. On average, analysts expect EPS of -$0.46 for the current quarter, with a high estimate of -$0.17 and a low estimate of -$0.63, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.09 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$0.31 and -$1.29 for the fiscal current year, implying an average EPS of -$0.83. EPS for the following year is $0.07, with 16 analysts recommending between $0.81 and -$0.64.
Revenue Estimates
20 analysts predict $628.92M in revenue for the current quarter. It ranges from a high estimate of $682M to a low estimate of $619.99M. As of the current estimate, Exact Sciences Corp.’s year-ago sales were $602.45M, an estimated increase of 4.40% from the year-ago figure. For the next quarter, 20 analysts are estimating revenue of $700.17M, an increase of 12.60% over than the figure of $4.40% in the same quarter last year. There is a high estimate of $721.08M for the next quarter, whereas the lowest estimate is $682M.
A total of 22 analysts have provided revenue estimates for EXAS’s current fiscal year. The highest revenue estimate was $2.87B, while the lowest revenue estimate was $2.82B, resulting in an average revenue estimate of $2.83B. In the same quarter a year ago, actual revenue was $2.5B, up 13.30% from the average estimate. Based on 21 analysts’ estimates, the company’s revenue will be $3.23B in the next fiscal year. The high estimate is $3.36B and the low estimate is $3.17B. The average revenue growth estimate for next year is up 14.10% from the average revenue estimate for this year.
